Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (4)
  • Open Access

    ARTICLE

    Calcium supplementation in colorectal cancer prevention: A systematic meta-analysis of adverse events

    XUE MEI LUO1, SHAHANAVAJ KHAN2,3,4,*, ABDUL MALIK2, FAHAD M. ALDAKHEEL5, ANIS AHMAD CHAUDHARY6, SHOUKI BAZARBASHI7, FATEMEH TABATABAIE8

    BIOCELL, Vol.46, No.3, pp. 759-767, 2022, DOI:10.32604/biocell.2022.016586 - 18 November 2021

    Abstract Despite the multiple systematic reviews and meta-analyses accumulating evidence on the preventive effect of calcium supplementation for colorectal cancer, most of the associated adverse effects are not systematically analyzed. The aim of the study is evaluating adverse events associated with calcium supplementation for colorectal cancer prevention through a systematic meta-analysis. We searched Medline, PubMed Central, EMBASE (Excerpta Medica database), Scopus, Cochrane Central Register of Controlled Trials, and Web of Science published in English from database inception up to 31 July 2019. In the current systematic meta-analysis, we included human studies (including cohort studies, clinical trials,… More >

  • Open Access

    ARTICLE

    Prediction of Suitable Candidates for COVID-19 Vaccination

    R. Sujatha1, B. Venkata Siva Krishna1, Jyotir Moy Chatterjee2, P. Rahul Naidu1, NZ Jhanjhi3,*, Challa Charita1, Eza Nerin Mariya1, Mohammed Baz4

    Intelligent Automation & Soft Computing, Vol.32, No.1, pp. 525-541, 2022, DOI:10.32604/iasc.2022.021216 - 26 October 2021

    Abstract In the current times, COVID-19 has taken a handful of people’s lives. So, vaccination is crucial for everyone to avoid the spread of the disease. However, not every vaccine will be perfect or will get success for everyone. In the present work, we have analyzed the data from the Vaccine Adverse Event Reporting System and understood that the vaccines given to the people might or might not work considering certain demographic factors like age, gender, and multiple other variables like the state of living, etc. This variable is considered because it explains the unmentioned variables… More >

  • Open Access

    ARTICLE

    Abnormal Coronary Anatomy in Patients with Transposition of the Great Arteries and Atrial Switch: A Predictor of Serious Cardiac Adverse Events?

    Yoann Perreux1, Marie Alexandre Chaix2, Anna Kamp3, François-Pierre Mongeon2, Magali Pham2, Loïc Boussel1, Roland Henaine1, Annie Dore2, Blandine Mondésert2, Sylvie Di-Filippo1, Paul Khairy2, Francis Bessiere1,*

    Congenital Heart Disease, Vol.15, No.6, pp. 473-482, 2020, DOI:10.32604/CHD.2020.013032 - 02 November 2020

    Abstract Sudden cardiac death and heart failure are well known long-term complications after atrial switch for D-transposition of the great arteries (D-TGA). Right systemic ventricular dysfunction is common and myocardial ischemia has been implicated as a putative mechanism for sudden death, with coronary anomalies prevalent in 30% of cases. We sought to assess an association between adverse events and coronary anomalies in patients with D-TGA and atrial switch surgery. An observational study was conducted in 3 tertiary centers (Montreal Heart Institute, Canada, Nationwide Children’s hospital, Chicago, USA and Hopital cardiologique Louis Pradel de Lyon, France). Adults… More >

  • Open Access

    REVIEW

    What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature

    Caroline Jamison*, Debra Nelson, Mete Eren, Dron Gauchan, Ryan Ramaekers, Max Norvell, Mehmet Sitki Copur

    Oncology Research, Vol.23, No.1-2, pp. 1-5, 2015, DOI:10.3727/096504015X14452563485986

    Abstract Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg once daily after demonstration of the same efficacy with less toxicity. Some patients require significant dose reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients may require further dose reductions due to substantial toxicity while maintaining good control of their disease. We report two CP-CML patients achieving and maintaining major molecular responses More >

Displaying 1-10 on page 1 of 4. Per Page